Drug Discovery World
Dr. Stephen Naylor & Judge M. Schonfeld, Winter 2014
The pharmaceutical industry is still beleaguered by escalating costs, stagnant productivity and protracted timelines as it struggles to bring therapeutic drugs to market. This situation has been compounded by a ravenous generic drug sector, and patients that have morphed into a discerning consumer population.
The growing interest, activity and productivity in Drug Repurposing, Drug Repositioning and Drug Rescue (DRPx) appears to offer some encouragement in finding solutions to the myriad of problems the pharmaceutical companies must overcome. Here we describe the current status of DRPx, discuss the emerging consensus on terminology and describe the tools, technologies and approaches utilised in DRPx.
Nick Sireau, September 29, 2014
Bruce Bloom is just one man, but he potentially knows a way to save millions of lives. Addressing a room full of pharma executives at a conference in Boston, he commands their full attention. He speaks with authority and passion.The topic is one that industry has shirked for too long. It’s about how to find new purposes for existing drugs when there’s no intellectual property left to protect. Most of us don’t realize that many of the drugs we rely upon regularly can be used for many different, often unrelated, illnesses...
Carolyn Graybeal, August 22, 2014
Each year in the U.S. millions of dollars' worth of useable medication is destroyed. While at the same time one in four working adults cannot afford their medication. It is a confusing and unnecessary contradiction.
Fortunately innovative organizations recognize that by recycling or repurposing medication it is possible to limit waste and conserve resources while helping individuals live healthier lives.
June 18, 2014
New web portal, built in collaboration with GlobalCures, will accelerate the open medical research approach to discover affordable, effective repurposed therapies
Dr. Bruce Bloom
The current medical solution industry, with amazing scientists and businesspeople working as hard as they can, is not creating treatments and cures for most of the world's diseases. Pharma in 2013 is using a fifty-year-old business model to leverage current knowledge and technology, but that is generating few new treatments, and each treatment increases healthcare costs. Read More
by Shawn Radcliffe, January 14, 2014
Researchers are testing existing drugs and compounds as they search for new cancer treatments hidden in plain site.
Blood pressure medications, antidepressants, antipsychotics: these may seem like unlikely cancer fighters, but in the search for effective new treatments, researchers are casting a wider net in hopes of finding existing compounds that improve patients' chances of survival.
In addition to providing alternative treatments, repurposed—or repositioned—drugs, as they are called, can also help researchers understand how a particular disease works or identify new molecular targets that can lead to even more effective drugs. Read full article here
Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases
Repurposing has the objective of targeting existing drugs and failed, abandoned, or yet-to-be-pursued clinical candidates to new disease areas. The open-source model permits for the sharing of data, resources, compounds, clinical molecules, small libraries, and screening platforms to cost-effectively advance old drugs and/or candidates into clinical re-development. Clearly, at the core of drug-repurposing activities is collaboration, in many cases progressing beyond the open sharing of resources, technology, and intellectual property, to the sharing of facilities and joint program development to foster drug-repurposing human-capacity development. A variety of initiatives under way for drug repurposing, including those targeting rare and neglected diseases, are discussed in this review and provide insight into the stakeholders engaged in drug-repurposing discovery, the models of collaboration used, the intellectual property-management policies crafted, and human capacity developed. Read full article
The true cost of drugs that fail in clinical trials should be measured by far more than the cash poured into the development process. Everyone loses something, whether it be the patients who are waiting for new treatments or the companies losing resources that could have gone back into bolstering R&D.
Some of the investment into these failed or shelved drugs can be recouped by giving them a second and often lower-risk chance in a new indication. This is known as drug repositioning, drug repurposing or drug rescue. It may be carried out by the company that invented the drug, but it’s more commonly pursued these days by smaller, more specialized companies.
Conducting medical research for drug rediscovery is a growing challenge, as the amount that is spent on it is minimal. However, there are many advantages with this method that are being overlooked See full article here
Drug Repurposing Finding new uses for approved drugs and shelved drug candidates is gaining steam as a pharmaceutical development strategy.
This fall, at least three conferences will bring together researchers to discuss how finding new uses for known drug compounds can be a strategy for both clinical development and business growth. A few years ago, no such conferences existed. The attendee lists show that interest is widespread among large pharmaceutical companies, small biotech firms, government agencies, academic groups, and nonprofit organizations alike.
November, 2012 on Creators.com
Think of it as Goodwill versus Bloomingdale's — except with medicine.
Today most researchers trying to cure a disease are like designers. They start from scratch in a lab, trying to create something unique and miraculous (and, some hope, lucrative). The odds against them are terrible — for every 10,000 new drugs tested, one actually gets to patients — and the expense is enormous, too; $250 billion in research a year yields maybe 30 new drugs.
Isn't there an alternative?
There is. Call them thrift shop drugs — drugs that were created for some other people with some other disease but that just might work on another ailment, too.
Northbrook Star By Karie Angell Luc July 23, 2012 6:08AM
The longest day of golf has a hole-in-goal of shortening the distance to finding a cure for pediatric brain tumors.
Green Acres Country Club of Northbrook at 916 Dundee Road will host 24 players Monday who will take a swing at 1,400 combined holes of golf to raise $60,000 for pediatric tumor research via the Chicago philanthropicorganization Partnership for Cures.
“There is a personal connection,’ said Steve Goldsher of Northbrook, a print procurement consultant and also Partnership for Cures (volunteer) executive board member. “Every year (18 year history), we choose a research project to fund with this year being for recurrent pediatric brain tumors. This year’s research project was inspired by my relationship with the Wehrs and Pete (Weiss) and his family.”
May 14, 2010
How the road from promising scientific breakthrough to real-world remedy has become all but a dead end.
By Sharon Begley and Mary Carmichael
From 1996 to 1999, the U.S. food and Drug Administration approved 157 new drugs. In the comparable period a decade later—that is, from 2006 to 2009—the agency approved 74. Not among them were any cures, or even meaningfully effective treatments, for Alzheimer's disease, lung or pancreatic cancer, Parkinson's disease, Huntington's disease, or a host of other afflictions that destroy lives.